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We would like to reply on the comment by Christiansen & 
Hess [1] on our article “Locoregional failure analysis in head 
and neck cancer patients treated with IMRT” [3] in Strahlen-
ther Onkol 2007;183:417–25 (No. 8).
The authors state that our study results do considerably 
modify the widely accepted clinical target volume (CTV) de-
finitions for head and neck cancer (HNC) published by Gre-
goire et al. [2]. This statement requires some precision, as Gre-
goire et al. did not recommend CTVs related to specific HNC 
situations, but offered a highly appreciated anatomic image 
atlas of the relevant lymph node regions in HNC, which per 
se are well known for decades (original article, p. 234, under 
“6. Discussion”: “These guidelines do not intend to give any 
recommendations for the optimal treatment strategy for node 
negative patients with a head neck primary, or the selection of 
various levels that require treatment”).
As described in our methods, we are somewhat more res-
trictive in the elective irradiation of node negative neck sides, 
compared to the recommendations of many RTOG protocols, 
e.g., with respect to the upper level II (often not going up to 
the skull base on the noninvolved neck side), or the medial 
retropharyngeal node groups, or regarding the submandibular 
groups in many patients with other than oral cavity tumors, 
respectively. However, results of a recent update of our in-
tensity modulated radiotherapy (IMRT) cohort of meanwhile 
410 curatively irradiated patients (01/2002–04/2007) confirm
the appropriateness of chosen planning target volumes (PTVs),
as no nodal relapses developed in initially noninvolved 
lymphatic areas, and no additional failures out of boost areas 
developed in the meantime.
Unfortunately, the authors do not give any information 
about their own practice of IMRT PTV/CTV and treatment 
schedules.
The authors state, that the follow-up time of 2 years is too 
short. In concordance with many published reports in the lite-
rature, our updated results again confirm a 2 year follow-up 
time being long enough to draw reliable conclusions in HNC, 
as only two out of 89 events occurred later than 2 years post 
IMRT (Figure 1).
Concerning the other points issued by Christiansen & 
Hess, combined chemotherapy should be considered the stan-
dard treatment in HNC today. Slight dose escalation using si-
multaneously integrated boost (SIB) IMRT is recently under 
investigation in a prospective study set up at our institution 
(started spring 2007). Dose escalation and variation of the 
fractionation regimen have to be performed very carefully: 
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Figure 1. 2-year locoregional control rates in 410 patients. LC: local con-
trol; NC: nodal control.
Abbildung 1. 2-Jahres-Lokalkontrollraten bei 410 Patienten. LC: lokale 
Kontrolle; NC: nodale Kontrolle. 
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based on the generally accepted treatment regimens as well 
as considering the already high locoregional control rate in 
small  and intermediate sized tumors, we regard the margin 
for a dose escalation in HNC as rather limited. Additional-
ly, we think the radiooncologic community may obtain more 
important advances in the treatment of HNC by increasing 
research activities on molecular profiling, basic mechanisms 
of radiosensitivity, combined treatment targeting agents, etc. 
Radiation oncologic research seems too much focused on the 
dose and volume paradigms, compared with the research ac-
tivities on molecular mechanisms and combined treatment of 
medical oncology.
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